- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Fair Value
An estimate of a Karyopharm's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
6.210
7.500
52 wk Range
3.510
16.950
KPTI Financial Summary
A brief financial summary of Karyopharm Therapeutics Inc as well as the most significant critical numbers from each of its financial reports. In addition, some financial ratios derived from these reports are featured. Users can opt to see 4 periods of either annual or quarterly information.
Key Ratios
Statements Highlights
| Period Ending: | 2015 31/12 | 2016 31/12 | 2017 31/12 | 2018 31/12 | 2019 31/12 | 2020 31/12 | 2021 31/12 | 2022 31/12 | 2023 31/12 | 2024 31/12 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
Total Revenues | aa.aa | aa.aa | aa.aa | aa.aa | aa.aa | 108.09 | 209.82 | 157.07 | 146.03 | 145.24 | |
Gross Profit | aa.aa | aa.aa | aa.aa | aa.aa | aa.aa | 105.38 | 206.42 | 151.86 | 141.09 | 139.23 | |
Operating Income | aa.aa | aa.aa | aa.aa | aa.aa | aa.aa | -171.85 | -98.27 | -142.2 | -129.54 | -119.44 | |
Net Income | aa.aa | aa.aa | aa.aa | aa.aa | aa.aa | -196.27 | -124.09 | -165.29 | -143.1 | -76.42 | |
Total Assets | aa.aa | aa.aa | aa.aa | aa.aa | aa.aa | 313.05 | 305.31 | 358.17 | 240.44 | 164.42 | |
Total Current Liabilities | aa.aa | aa.aa | aa.aa | aa.aa | aa.aa | 60.2 | 73.72 | 65.91 | 69.48 | 92.26 | |
Total Equity | aa.aa | aa.aa | aa.aa | aa.aa | aa.aa | 50.55 | -79.67 | -16.66 | -136.21 | -186.02 | |
Levered Free Cash Flow | aa.aa | aa.aa | aa.aa | aa.aa | aa.aa | -88.16 | -58.64 | -101.35 | -39.95 | -77.12 | |
Cash from Operations | aa.aa | aa.aa | aa.aa | aa.aa | aa.aa | -160.23 | -107.12 | -149.55 | -92.72 | -127.49 | |
Cash from Investing | aa.aa | aa.aa | aa.aa | aa.aa | aa.aa | -53.69 | 141.84 | -104.26 | 7.94 | 95.47 | |
Cash from Financing | aa.aa | aa.aa | aa.aa | aa.aa | aa.aa | 172.08 | 73.65 | 193.74 | 1.12 | 41.65 | |
Net Change in Cash | aa.aa | aa.aa | aa.aa | aa.aa | aa.aa | -41.57 | 108.32 | -60.56 | -83.69 | 9.62 | |
* In Millions of USD (except for per share items)
Analyst Ratings
5 Buy
2 Hold
0 Sell
Ratings:
7 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 25.917
(+247.41% Upside)
FAQ
What were Karyopharm's earnings for the latest quarter?
The Karyopharm EPS (TTM) is -14.62. Karyopharm reported sales of 37.93, net income of -37.25, and EPS of -4.32 for the latest quarter.
What was Karyopharm's net income for the latest quarter?
Karyopharm's net income for the latest quarter was -37.25.
How did Karyopharm's performance compare year-over-year in the latest quarter?
The company's revenue moved from 30.02 in the previous quarter to 37.93 in the latest quarter, and net income moved from -23.46 to -37.25 compared to the previous quarter.
What is Karyopharm's net profit margin on a TTM basis?
Karyopharm's trailing twelve months (TTM) net profit margin is -52.62%.
How does Karyopharm's debt to equity ratio compare to industry standards?
Karyopharm's total debt-to-equity ratio is -110.54%.
What is Karyopharm's return on investment on a TTM basis?
Karyopharm's trailing twelve months (TTM) return on investment (ROI) is 66.60%.
Did Karyopharm gain or lose cash last quarter?
In the latest quarter, Karyopharm's net change in cash was -0.05 million.
What were Karyopharm's total assets and liabilities in the latest quarter?
As of the latest quarter, Karyopharm reported total assets of 104.88 million and total liabilities of 99.22 million.
How has Karyopharm's total revenue grown this year?
Karyopharm's total revenue was 30.02 in the previous quarter and 37.93 in the latest quarter.
What is Karyopharm's gross margin on a TTM basis?
Karyopharm's trailing twelve months (TTM) gross margin is 101.02%.
What was Karyopharm's revenue per share for the latest quarter?
Karyopharm's revenue per share for the latest quarter was 44.21.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.